The use of this technique as a complementary therapy for SIRS patients was based on the physiopathology of SIRS and the possible role of HBOT in the inflammatory process, as it may decrease proinflammatory cytokine production and the release of tumor necrosis factor (TNF-α), while increasing the production of vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF), both known for their respective roles in the inflammatory process [11,12]. The gene discussed is VEGFA; the disease is systemic inflammatory response syndrome.